Skip to main content

Tailored treatment for signet ring cell gastric cancer

Updates in Surgery volume 70, pages 167–171 (2018)Cite this article

Abstract

Gastric cancer with Laurèn diffuse types is increasing in the West. The raising trend is more evident when considering signet ring cells (SRC) histology. However, to control the biologic potential of this GC subtype, some hypotheses of tailored therapeutic strategies for SRC cancers have been made. A review of the literature was performed using the key words “signet ring cells” AND “gastric cancer”. Results of literature review were descriptively reported. Endoscopic submucosal dissection (ESD), according to the Japanese extended criteria, could be a therapeutic option for early SRC tumours. However, according to the evidences from more recent studies, indications for ESD to these tumours types should be carefully considered. Concerning the optimal surgical treatment, considering the high lymphotropism and infiltrating behaviour of SRC histotype, the extension of gastric resection should be wider than for intestinal type cancer and laparoscopic surgery should be performed carefully. Moreover, D3 lymphadenectomy could provide a benefit in diffuse-type and SRC histology. The role of surgery in gastric cancer with peritoneal carcinomatosis is still debated and studies on this topic should stratify the good results according to GC histotype. Finally, despite the evidences of chemoresistance in SRC, ongoing randomized trials suggest that multimodal therapy could be the best treatment. Based on the assumption that SRC tumours have specific features, they deserve a specific multimodal treatment. However, a preliminary step to generate strong evidences in this field is the standardization of terminology used to define signet ring cells carcinoma.

This is a preview of subscription content, access via your institution.

Access options

Buy single article

Instant access to the full article PDF.

43,34 €

Price includes VAT (Finland)
Tax calculation will be finalised during checkout.

References

  1. International Agency For Research On Cancer (2012) GLOBOCAN 2012: estimated cancer incidence, Mortality and Prevalence Worldwide

  2. Marrelli D, Pedrazzani C, Morgagni D, de Manzoni G, Pacelli F, Coniglio A, Marchet A, Saragoni L, Giacopuzzi S, Roviello F, on behalf of the Italian Research Group for Gastric Cancer (IRGGC) (2011) Changing clinical and pathological features of gastric cancer over time. Br J Surg 98:1273–1283

    Article  PubMed  CAS  Google Scholar 

  3. Wu H, Rusiecki JA, Zhu K, Potter J, Devesa SS (2009) Stomach carcinoma incidence patterns in the United States by histologic type and anatomic site. Cancer Epidemiol Biomarkers Prev 18(7):1945–1952

    Article  PubMed  PubMed Central  Google Scholar 

  4. Henson DE, DittusC YounesM et al (2004) Differential trends in the intestinal and diffuse types of gastric carcinoma in the United States, 1973–2000: increase in the signet ring cell type. Arch Pathol Lab Med 128:765–770

    PubMed  Google Scholar 

  5. Piessen G, Messenger M, Leteurtre E, Jean-Pierre T, Mariette C (2009) Signet ring cell histology is an independent predictor of poor. prognosis in gastric adenocarcinoma regardless of tumoral clinical presentation. Ann Surg 250(6):878–887

    Article  PubMed  Google Scholar 

  6. Taghavi S, Jayarajan SN, Davey A, Willis AI (2012) Prognostic significance of signet ring gastric cancer. J Clin Oncol 30(28):3493–3498

    Article  PubMed  PubMed Central  Google Scholar 

  7. Bamboat ZM, Tang LH, Vinuela E, Kuk D, Gonen M, Shah MA, Brennan MF, Coit DG, Strong VE (2014) Stage-stratified prognosis of signet ring cell histology in patients undergoing curative resection for gastric adenocarcinoma. Ann Surg Oncol 21(5):1678–1685

    Article  PubMed  Google Scholar 

  8. Chon HJ, Hyung WJ, Kim C et al (2017) Differential prognostic implications of gastric signet ring cell carcinoma: stage adjusted analysis from a single high-volume center in Asia. Gastric Cancer 265:946–953

    Google Scholar 

  9. Gotoda T, Yamamoto H, Soetikno RM (2006) Endoscopic submucosal dissection of early gastric cancer. J Gastroenterol 41:929–942

    Article  PubMed  Google Scholar 

  10. Ahn JY, Jung HY, Choi KD et al (2011) Endoscopic and oncologic outcomes after endoscopic resection for early gastric cancer: 1370 cases of absolute and extended indications. Gastrointest Endosc 74:485–493

    Article  PubMed  Google Scholar 

  11. Association Japanese Gastric Cancer (2011) Japanese gastric cancer treatment guidelines 2010 (ver. 3). Gastric Cancer 14:113–123

    Article  Google Scholar 

  12. Chung JW, Jung HY, Choi KD et al (2011) Extended indication of endoscopic resection for mucosal early gastric cancer: analysis of a single center experience. J Gastroenterol Hepatol 26(5):884–887

    Article  PubMed  Google Scholar 

  13. Hirasawa T, Fujisaki J, Fukunaga T et al (2010) Lymph node metastasis from undifferentiated-type mucosal gastric cancer satisfying the expanded criteria for endoscopic resection based on routine histological examination. Gastric Cancer 13:267–270

    Article  PubMed  Google Scholar 

  14. Laurén PA, Nevalainen TJ (1993) Epidemiology of intestinal and diffuse types of gastric carcinoma. A time-trend study in Finland with comparison between studies from high- and low-risk areas. Cancer 71:2926–2933

    Article  PubMed  Google Scholar 

  15. Fléjou JF (2011) WHO classification of digestive tumors: the fourth edition. Ann Pathol 31:27–31

    Article  Google Scholar 

  16. Japanese Gastric Cancer Association (1998) Japanese classification of gastric carcinoma—2nd English edition. Gastric Cancer 1:10–24

    Article  PubMed  CAS  Google Scholar 

  17. Hölscher AH, Drebber U, Mönig SP, Schulte C, Vallböhmer D, Bollschweiler E (2009) Early gastric cancer lymph node metastasis starts with deep mucosal infiltration. Ann Surg 250(5):791–797

    Article  PubMed  Google Scholar 

  18. Popiela T, Kulig J, Kolodziejczyk P, Sierzega M, Polish Gastric Cancer Study Group (2002) Long-term results of surgery for early gastric cancer. Br J Surg 89(8):1035–1042

    Article  PubMed  CAS  Google Scholar 

  19. Pokala SK, Zhang C, Chen Z, Gamboa AM, Cristofaro SL, Keilin SA, Cai Q, Willingham FF (2018) Incidence, survival, and predictors of lymph node involvement in early-stage gastric signet ring cell carcinoma in the US. J Gastrointest Surg. https://doi.org/10.1007/s11605-017-3500-4

    PubMed  Article  Google Scholar 

  20. Park JM, Kim SW, Nam KW, Cho YK, Lee IS, Choi MG, Chung IS, Song KY, Park CH, Jung CK (2009) Is it reasonable to treat early gastric cancer with signet-ring cell histology by endoscopic resection? Analysis of factors related to lymph-node metastasis. Eur J Gastroenterol Hepatol 21(10):1132–1135

    Article  PubMed  Google Scholar 

  21. Kang KSH, Kim JS, Moon HS, Lee ES et al (2017) Signet ring cell carcinoma of early gastric cancer, is endoscopic treatment really risky? Medicine 96:33

    Google Scholar 

  22. Wang Z, Zhang X, Hu J, Zeng W, Liang J, Zhou H, Zhou Z (2014) Predictive factors for lymph node metastasis in early gastric cancer with signet-ring cell histology and their impact on the surgical strategy: analysis of single institutional experience. J Surg Res 191(1):130–133

    Article  PubMed  Google Scholar 

  23. Lee SH, Jee SR, Kim JH et al (2015) Intramucosal gastric cancer: the rate of lymph node metastasis in signet ring cell carcinoma is as low as that in well-differentiated adenocarcinoma. Eur J Gastroenterol Hepatol 27:170–174

    Article  PubMed  Google Scholar 

  24. Guo CG, Zhao DB, Liu Q et al (2015) Risk factors for lymphnode metastasis in early gastric cancer with signet ring cell carcinoma. J Gastrointest Surg 19:1958–1965

    Article  PubMed  Google Scholar 

  25. Kim MN, Kim HK, Shim CN, Lee HJ, Lee H, Park JC, Shin SK, Lee SK, Lee YC (2014) Tumour size is related to the curability of signet-ring cell early gastric cancer with endoscopic submucosal dissection: a retrospective single centre study. Dig Liver Dis. 46(10):898–902

    Article  PubMed  Google Scholar 

  26. Lee JH, Choi IJ, Kook MC, Nam BH, Kim YW, Ryu KW (2010) Risk factors for lymph node metastasis in patients with early gastric cancer and signet ring cell histology. Br J Surg 97:732

    Article  PubMed  CAS  Google Scholar 

  27. de Manzoni G, Baiocchi GL, Framarini M (2014) The SIC-GIRCG 2013 consensus conference on gastric cancer. Updates Surg 66:1–6

    Article  PubMed  Google Scholar 

  28. Moehler M, Baltin CT, Ebert M, Fischbach W, Gockel I, Grenacher L et al (2015) International comparison of the German evidence-based S3-guidelines on the diagnosis and multimodal treatment of early and locally advanced gastric cancer, including adenocarcinoma of the lower esophagus. Gastric Cancer 18(3):550–563

    Article  PubMed  Google Scholar 

  29. Kelly KJ, Selby L, ChouJF Dukleska K, Capanu M, Coit DG et al (2015) Laparoscopic versus open gastrectomy for gastric adenocarcinoma in the west: a case–control study. Ann Surg Oncol 22(11):3590–3596

    Article  PubMed  PubMed Central  Google Scholar 

  30. Esaki Y, Hirayama R, Hirokawa K (1990) A comparison of patterns of metastasis in gastric cancer by histologic type and age. Cancer 65(9):2086–2090

    Article  PubMed  CAS  Google Scholar 

  31. de Manzoni G, Verlato G, Bencivenga M, Marrelli D, Di Leo A, Giacopuzzi S, Cipollari C, Roviello F (2015) Impact of super-extended lymphadenectomy on relapse in advanced gastric cancer. Eur J Surg Oncol 41(4):534–540

    Article  PubMed  Google Scholar 

  32. Kim DY, Park YK, Joo JK et al (2004) Clinicopathological characteristics of signet ring cell carcinoma of the stomach. ANZ J Surg 74:1060–1064

    Article  PubMed  Google Scholar 

  33. Desiderio J, Chao J, Melstrom L, Warner S, Tozzi F, Fong Y, Parisi A, Woo Y (2017) The 30-year experienced A meta-analysis of randomised and high-quality non-randomised studies of hyperthermic intraperitoneal chemotherapy in the treatment of gastric cancer. Eur J Cancer 79:14

    Article  Google Scholar 

  34. Mezhir JJ, Shah MA, Jacks LM, Brennan MF, Coit DG, Strong VE (2011) Positive peritoneal cytology in patients with gastric cancer: natural history and outcome of 291 patients. Indian J Surg Oncol 2(1):16–23

    Article  PubMed  PubMed Central  Google Scholar 

  35. Badgwell B, Blum M, Das P, Estrella J, Wang X, Ho L, Fournier K, Royal R, Mansfield P, Ajani J (2017) Phase II trial of laparoscopic hyperthermic intraperitoneal chemoperfusion for peritoneal carcinomatosis or positive peritoneal cytology in patients with gastric adenocarcinoma. Ann Surg Oncol 24(11):3338–3344

    Article  PubMed  Google Scholar 

  36. Kim SW (2014) The result of conversion surgery in gastric cancer patients with peritoneal seeding. J Gastric Cancer 14(4):266–270

    Article  PubMed  PubMed Central  Google Scholar 

  37. Cunningham D, Allum WH, Stenning SP et al (2006) Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 355:11–20

    Article  PubMed  CAS  Google Scholar 

  38. Heger U, Blank S, Wiecha C, Langer R, Weichert W, Lordick F et al (2014) Is preoperative chemotherapy followed by surgery the appropriate treatment for signet ring cell containing adenocarcinomas of the esophagogastric junction and stomach? Ann Surg Oncol 21(5):1739–1748

    Article  PubMed  Google Scholar 

  39. Messager M, Lefevre JH, Pichot-Delahaye V, Souadka A, Piessen G, Mariette C, FREGAT working group–FRENCH (2011) The impact of perioperative chemotherapy on survival in patients with gastric signet ring cell adenocarcinoma a multicenter comparative study. Ann Surg 254:684–693

    Article  PubMed  Google Scholar 

  40. Piessen G, Messager M, Le Malicot K, Robb WB, Di Fiore F, Guilbert M et al (2013) Phase II/III multicentre randomised controlled trial evaluating a strategy of primary surgery and adjuvant chemotherapy versus peri-operative chemotherapy for resectable gastric signet ring cell adenocarcinomas—PRODIGE 19–FFCD1103–ADCI002. BMC Cancer 13:281

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  41. Al-Batran SE, Hofheinz RD, Pauligk C (2016) Histopathological regression after neoadjuvant docetaxel, oxaliplatin, fluorouracil, and leucovorin versus epirubicin, cisplatin, and fluorouracil or capecitabine in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4-AIO): results from the phase 2 part of a multicentre, open-label, randomised phase 2/3 trial. Lancet Oncol 17:1697–1708

    Article  PubMed  CAS  Google Scholar 

Download references

Funding

None

Author information

Affiliations

  1. General and Upper GI Surgery Division, University of Verona, Piazzale Aristide Stefani 1, 37126, Verona, Italy

    V. Mengardo, M. Bencivenga, Mariagiulia Dal Cero & S. Giacopuzzi

  2. Department of Surgery-Division of General Surgery Fondazione Poliambulanza, Istituto Ospedaliero Brescia, Brescia, Italy

    E. Treppiedi

Authors
  1. V. Mengardo
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. E. Treppiedi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. M. Bencivenga
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Mariagiulia Dal Cero
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. S. Giacopuzzi
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to V. Mengardo.

Ethics declarations

Conflict of interest

The Authors declare that they have no conflict of interest.

Research involving human participants and/or animals

The research does not involve human participants and/or animals.

Informed consent

There was no need to get informed consent.

Additional information

The article is part of topical collection on Gastric Cancer Surgery.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Mengardo, V., Treppiedi, E., Bencivenga, M. et al. Tailored treatment for signet ring cell gastric cancer. Updates Surg 70, 167–171 (2018). https://doi.org/10.1007/s13304-018-0550-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13304-018-0550-4

Keywords

  • Gastric cancer
  • Signet ring cell
  • Tailored treatment